Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Major 2026-08-18 catalyst: positive Phase 3 LUCIDITY topline data for avexitide showed a 55% reduction in clinically significant hypoglycemic events versus placebo, with shares up about 78% over 21 trading days.
Loading chart data...
Idea window: 8/18/2026 – 8/25/2026Sector: Healthcare
AI Analyst Overview
Loading AI Analyst data...
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Aug 18 | Aug 25 | AMLX | Amylyx Pharmaceuticals, Inc. | Major 2026-08-18 catalyst: positive Phase 3 LUCIDITY topline data for avexitide showed a 55% reduction in clinically significant hypoglycemic events versus placebo, with shares up about 78% over 21 trading days. | Active | +0.0% |